Sign In  |  Register  |  About Santa Clara  |  Contact Us

Santa Clara, CA
September 01, 2020 1:39pm
7-Day Forecast | Traffic
  • Search Hotels in Santa Clara

  • ROOMS:

NaturalShrimp Announces Filing of Joint Patent Application

Strengthens Intellectual Property (IP) Protection Related to Electrocoagulation (EC) and HydroGas Technologies


DALLAS, TX - (NewMediaWire) - October 06, 2022 - NaturalShrimp, Inc. (OTCQB: SHMP), a Biotechnology Aquaculture Company that has developed and patented the first shrimp-focused commercially operational RAS (Recirculating Aquaculture System), and its technology partner, Hydrenesis, Inc., today announced the filing a United States joint patent application to further strengthen the Intellectual

Property (IP) protection related to Electrocoagulation (EC) and HydroGas technologies.

EC and Hydrogas have shown efficacy in improving welfare scores not only in shrimp production, but also in finfish, as evidenced by third party trials conducted at a leading aquaculture testing facility in Bergen, Norway. The newly filed patent application involves technology co-developed by NaturalShrimp and Hydrenesis as a strategy to augment existing IP protection with additional, and more advanced methods and apparatus. NaturalShrimp will license the EC and HydroGas technologies for various aquatic species.

 “We are constantly looking for ways to improve efficiency and broad applications for our technologies, not just in shrimp, but also in additional aquatic species,” said Tom Untermeyer, Chief Operations Officer and Chief Technology Officer. “Our work with Hydrenesis to develop the new technologies has strengthened our engineering capabilities, and we look forward to ongoing co-development work with Hydrenesis to enhance our IP portfolio even further.”

Gerald Easterling, Chief Executive Officer, added, “As we continue to expand our shrimp production capabilities, having additional IP such as this will only strengthen our presence both domestically and internationally, as we expand over the next several years.”

David Antelo, Hydrenesis President and CEO, also added, “The cohesive relationship between the NaturalShrimp and Hydrenesis engineering teams has accelerated the development of our technologies as we focus on an aggressive growth trajectory. This joint patent represents more than 12 months of collaboration and is expected to add shareholder value as the commercialization phases unfold.”

About NaturalShrimp

NaturalShrimp, Inc. is a publicly traded aquaculture Company, headquartered in Dallas, with production facilities located near San Antonio, Texas and Webster City, Iowa. The Company has developed the first commercially viable system for growing shrimp in enclosed, salt-water systems, using patented technology to produce fresh, never frozen, naturally grown shrimp, without the use of antibiotics or toxic chemicals. NaturalShrimp systems can be located anywhere in the world to produce gourmet-grade Pacific white shrimp. For more information visit

Forward-Looking Statements

This press release contains a number of forward-looking statements that reflect management's current views with respect to future events and financial performance. Forward-looking statements are projections in respect of future events or our future financial performance. In some cases, you can identify forward-looking statements by terminology such as “may,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or the negative of these terms or other comparable terminology. These statements include statements regarding the intent, belief or current expectations of us and members of our management team, as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risk and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties and other factors, including the risks set forth in the section entitled “Risk Factors” in the Company's Annual Report on Form 10-K for the fiscal year ended March 31, 2021, any of which may cause our company’s or our industry’s actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied in our forward-looking statements.

Investor Relations Contact

Chris Tyson

Executive Vice President

MZ North America

Direct: 949-491-8235



Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Copyright © 2010-2020 & California Media Partners, LLC. All rights reserved.